Neuronetics

Neuronetics, Inc. is a privately held medical device company focused on developing non-invasive therapies for psychiatric and neurological disorders using MRI-strength magnetic field pulses. It is the first and only company to have a non-systemic and non-invasive depression treatment cleared by the FDA for patients who have not benefited from prior antidepressant treatment^*. Based in Malvern, PA, Neuronetics is the leader in the development of NeuroStar TMS Therapy (transcranial magnetic stimulation), a non-invasive form of neuromodulation. Incorporated in 2003, the company began by licensing a revolutionary patented coil design from Emory University. Using this new, more efficient coil, the company’s first TMS Therapy research units were built and used to complete the largest clinical trial ever conducted (23 international sites) evaluating NeuroStar TMS Therapy^® in the treatment of major depression. Since completing clinical trials, The company’s Product Development group has continued to refine its early research device to develop a high quality, efficient, user friendly commercial unit – the NeuroStar TMS Therapy^® system. In October of 2008, the NeuroStar TMS Therapy system received FDA clearance for the treatment of major depressive disorder in patients who have failed to receive benefit from prior antidepressant therapy.^* NeuroStar TMS Therapy is available by prescription only and is delivered under the supervision of a psychiatrist.